The clinical study to explore the effects of SGLT2-inhibitors or DPP-4 inhibitors in Japanese patients with type 2 diabetes.

The clinical study to explore the effects of SGLT2-inhibitors or DPP-4 inhibitors in Japanese patients with type 2 diabetes. - The clinical study to explore the effects of SGLT2-inhibitors or DPP-4 inhibitors.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020984

Enrollment

160

Registered

2016-02-28

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Dapagliflozin 5 mg once a day for 6months Sitagliptin 50 mg once a day for 6months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Outpatients with type 2 diabetes (HbA1c:6.5-9.4%) who were attended to Showa University Hospital (Tokyo, Japan) 2.Patients who are 20-65 years old 3.Patients who themselves can voluntarily provide consent to participate in this study

Exclusion criteria

Exclusion criteria: 1.Patients who are acute disease 2.Patients who are past history of hypersensitivity to anagliptin 3.Pregnant or woman of child-bearing potential 4.Patients whose eGFR are within 60mL/min/1.73m2 5.Patients who are judged as inappropriate for inclusion by phsicians

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
Small dense LDL-C, Large LDL-C HDL2,3-C, RLP-C, liver function, Fatty acid composition Amino acid composition, BW,BP, Central BP parameters, ABPM	—

Countries

Japan

Contacts

Public ContactToshiyuki Hayashi

Showa University School of Medicine Division of Diabetes and Endocrinology, Department of Internal Medicine

t-hayashi@med.showa-u.ac.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026